Cardialen: Cardialen Awarded $3 Million Federal Grant to Advance Therapy Designed to Treat Atrial Fibrillation for Improved Heart Failure Outcomes
Cardialen , Inc., has been awarded a $3 million National Institutes of Health (NIH) Phase IIb SBIR grant for the development of an implantable, low-energy therapy for the cardioversion of atrial fibrillation (AF).
Read full article »
Cardialen is a Minnesota-based medical device company that develops implantable cardioversion and defibrillation products for the treatment of atrial fibrillation.
Read more